The Revolving Door: Five Officials, Five Offices, and the Rules That Let Them Walk Through

By Jordan Gold and Valery Gold

November 9, 2026 · Public-records review · Records checked through November 9, 2026

An illustrative sample, not a census: what the public record shows, and does not show, about five officials who moved between Congress, four federal agencies and the industries those offices touched.

Somewhere in this country a dairy farmer is paying into a federal checkoff in a month when the milk check does not cover the feed bill. A retiree on Medicare is splitting pills to stretch a prescription. A family on a Gulf Coast fence line is reading about another export terminal. A household is paying a cable and broadband bill set by a company that a federal commission let grow. None of them will ever be in the room where the rules get written. That is the reason to read the record of the people who are.

This is a records review of five people who moved between public office and an industry their office touched, from drug law and drug regulation to farm policy, energy and telecommunications. Two of the five cases involve the drug industry, one through Congress and one through the FDA. We kept both because they show the same industry from two sides of government, lawmaking and regulation. The other three cases cover farm policy, energy and telecommunications. We chose them because the sequence is documented in public records, the stakes were large and each person's own account is on the record. They are an illustrative sample. They are not a representative or complete list, and they do not measure how often this happens. They are not here because we think these are uniquely bad people.

Let's be precise from the first line. In each of the five cases below, the moves we describe were lawful as far as the record shows. We found no charge, no conviction and no official finding of an ethics violation against any of them. Taking a private job after public service is not bribery. Sitting on a corporate board is not a payoff. The question here is a different one: what the rules allow, who carries the risk when they allow it, and whether the public can see enough to judge.

Suspicion is not proof. A sequence of dates is not a motive. But dates are what citizens have, so we read them in order and label what kind of claim each one is: documented fact, a critic's allegation, our inference, or an apparent conflict that no authority has adjudicated.

The rules of the road

Federal law does not bar former officials from working for the industries they oversaw. It mostly limits certain kinds of lobbying contact for a set period. Under 18 U.S.C. § 207, former senior executive-branch officials may not, for one year, knowingly make a communication to or appearance before their former agency "with the intent to influence" it on behalf of someone else, and "very senior" officials such as Cabinet secretaries face a two-year version that reaches more of the government. [10] The Honest Leadership and Open Government Act of 2007 extended the ban to two years for very senior executive personnel and for former senators, kept one year for former House members, and for the first time required House members to disclose private job negotiations within three business days and to recuse themselves from conflicted matters. [9]

Presidents have added their own pledges on top of the statute. President Obama's 2009 pledge, required of every appointee, had departing appointees agree to observe the § 207(c) contact ban for two years instead of one. [34] President Trump's 2017 pledge barred appointees from lobbying their former agency for five years and from working on specific-party matters involving a former employer for two years after appointment. [15] On January 19, 2021, Trump revoked that order, freeing everyone who had signed it from its commitments as of noon the next day. [24] President Biden's 2021 pledge restored a two-year bar on matters involving former employers and clients. [35]

Two other rules matter here. The ethics agreements these officials signed recite the criminal conflict-of-interest statute, 18 U.S.C. § 208: while in office, an official may not work on a matter affecting the financial interests of an organization with which they are "negotiating or have an arrangement concerning prospective employment." [14][31] And none of these rules treats board service, or an executive salary, as a lobbying contact. The cooling-off period quiets the phone line. It does not touch the paycheck.

1. Billy Tauzin: the bill, the vote, the job (Congress → PhRMA)

The office. W.J. "Billy" Tauzin, a Louisiana Republican the Los Angeles Times described as a 13-term member (NBC counted "a dozen terms"), chaired the House Energy and Commerce Committee, which the Times said gave him jurisdiction over the drug industry. [5][4]

What he did in office. Tauzin was one of 20 original cosponsors of H.R. 1, the Medicare Prescription Drug, Improvement, and Modernization Act, introduced June 25, 2003, and on July 14, 2003, the Speaker named him one of the House conferees who negotiated the final bill. [2] On November 22, 2003, at 5:53 a.m., the House adopted the conference report 220 to 215. Tauzin voted yea. [1] It became Public Law 108-173 on December 8, 2003. [2] NBC News reported that as chairman he "had a key role in drafting and passage" of the law. [4]

What the law did for the industry, and for patients. The law created Medicare's outpatient drug benefit, which brought coverage to seniors who had none. It also contained the noninterference clause: the Secretary of Health and Human Services "may not interfere with the negotiations between drug manufacturers and pharmacies and PDP sponsors." [3] ProPublica reported that the final bill "specifically barred the government from negotiating lower drug prices" and also blocked importation of cheaper drugs from Canada. [8] In 2022, Public Law 117-169, the Inflation Reduction Act, amended the clause to carve out the new Medicare drug price negotiation program. [3]

The job. NBC reported that in December 2003, the month the bill was signed, the Pharmaceutical Research and Manufacturers of America (PhRMA) was pursuing Tauzin to be its president, and that by early February 2004 he had announced he would not seek reelection. [4] In December 2004, PhRMA named him president, starting January 3, 2005, when he left Congress. [5] NPR, citing PhRMA's tax filing, reported his 2009 pay as a $2.1 million salary and a $2.3 million bonus, $4.6 million in total compensation including benefits, up from $4.4 million the year before. [6] He left PhRMA in mid-2010; NPR reported he then opened a lobbying firm with his son. [6]

The cooling-off record. Federal lobbying disclosures list Tauzin as a PhRMA lobbyist on filings for 2006 through 2010. PhRMA's filings for 2005, his first year out of the House, do not list him. [11] PhRMA's year-end 2006 report lists "TAUZIN, BILLY" with his covered official position given as "MEMBER OF CONGRESS," on issues including health and Medicare, with the House, the Senate, the FDA and the Medicare agency among the entities contacted. [46] He is still listed on PhRMA's report for the second quarter of 2010. [47] That timing is consistent with the one-year ban that then applied to former House members; we found no record that any authority examined his compliance. After PhRMA, disclosures list him as a lobbyist through his own firms and Alston & Bird for more than a decade, with a filing listing him as recently as 2026. [12] By late 2012, for example, his firm Tauzin Strategic Networks reported lobbying for Endo Pharmaceuticals, listing "Wilbert J. 'Billy' Tauzin" with the covered position "Member of Congress (LA-3)." [48]

His side of it. Tauzin insisted there was no relationship between his work on the Medicare bill and the job, and said the decision was shaped by his fight with intestinal cancer: "As I worked through my recovery, I realized that I wanted to work in an industry whose mission is no less than saving and enhancing lives." [4] In March 2006 he wrote to every member of Congress to deny that he negotiated the PhRMA job while working on the law. [4]

Was wrongdoing found? None that we could locate. In January 2004, Public Citizen, an advocacy group, asked the House ethics committee to investigate whether he had begun job talks while crafting the bill, and noted that House rules then only discouraged such negotiations. [7] We did not find a public committee response. NBC reported that watchdog groups agreed that even if he had done what he denies, "he would have broken no laws." [4]

How to read it. Documented: cosponsorship, his role as a conferee, the yea vote, the noninterference clause, the PhRMA presidency, the reported pay and the later lobbying registrations. Apparent conflict: PhRMA's reported pursuit of the chairman in the same month the bill became law. Unproven: that any job talks happened before the vote. Tauzin denies it, and we found no document showing it.

Put plainly: the House wrote a drug benefit that told the government not to bargain, and the chairman who helped write it went to lead the drugmakers' trade group. Legal, on this record. Documented. And it is exactly the kind of sequence that the 2007 rule now requires House members to disclose within three business days, with recusal from conflicted matters. [9]

2. Scott Gottlieb: from the commissioner's chair to Pfizer's boardroom (FDA → Pfizer board)

The office. Dr. Scott Gottlieb served as the 23rd Commissioner of Food and Drugs from May 11, 2017, to April 5, 2019. [13] He signed an ethics agreement before taking office. It required him to resign industry positions, including a GlaxoSmithKline role, sell holdings in more than a dozen client companies, and stay out of specific matters involving former employers and clients for a year. [14] His agreement noted that he would also be bound by President Trump's 2017 ethics pledge, which every appointee was required to sign. [14][15]

What he pushed. Gottlieb is a harder case than Tauzin, and fairness requires saying so first. His signature drug-pricing policies were aimed at competition. On July 18, 2018, he released the FDA's Biosimilars Action Plan and attacked brand-name drugmakers' "gaming tactics," "rebating schemes" and "patent thickets" that delay cheaper copies. [16] In the same speech he warned that "the shrapnel could also fray the fragile market-based rewards that support new innovation." [16] He was trying to push down prices while protecting incentives to invent. That is not a gift to incumbents.

Where Pfizer fit in. Pfizer sits on both sides of the fight: it sells brand-name drugs and it sells biosimilars. On May 15, 2018, during Gottlieb's tenure, the FDA approved Pfizer's Retacrit, which Pfizer called its third approved U.S. biosimilar, with a biosimilars pipeline of 11 molecules. [17] We found no record that Gottlieb personally decided it. On February 25, 2019, the FDA warned of a safety signal (pulmonary embolism and higher overall mortality) at the 10 mg twice-daily dose of Pfizer's arthritis drug Xeljanz in a trial the agency had required. Pfizer, at the FDA's recommendation, moved trial patients to the approved 5 mg dose. [18] Public Citizen, an advocacy group, later cited Milwaukee Journal Sentinel reporting that the FDA under Gottlieb took less aggressive action on Xeljanz than European regulators did. [19] That is a reported comparison and a critic's interpretation. It is not a finding that he favored Pfizer, and we have not independently tested it.

The job. On June 27, 2019, less than three months after he left the FDA, Pfizer's board elected him a director, effective immediately, and named him to its Regulatory and Compliance Committee and its Science and Technology Committee. [20] Pfizer's 2026 proxy reports his 2025 director pay at $393,500: $185,000 in cash, $205,000 in stock awards and $3,500 in other compensation. It lists him as chair of the Regulatory and Compliance Committee, a partner at the venture firm New Enterprise Associates and a senior fellow at the American Enterprise Institute. [21] The proxy discloses that Pfizer made a corporate-sponsorship payment to AEI in 2025, and says its review found the payment was ordinary-course and below the levels in its director-independence standards. [21] Shareholders reelected him on April 23, 2026. [22]

The criticism and his response. Sen. Elizabeth Warren wrote to him on July 1, 2019, that "this kind of revolving door influence-peddling smacks of corruption" and asked him to resign the seat. [23] That is a senator's accusation, not a finding. Gottlieb defended the move on CNBC, where he is a contributor: "I worked with some large drugmakers before I came into the agency," he said, and "I made no bones about the fact that I had expertise in life sciences and I made my living trying to promote innovation in this sector prior to coming to the agency." [23]

Was wrongdoing found? None that we located. A board seat is not a communication to or appearance before the FDA, so § 207 does not reach it. [10] The Trump pledge's five-year ban covered lobbying, not board service, and the pledge itself was revoked in January 2021. [15][24] We did not find public records showing when Pfizer first approached him. That is the fact that matters under § 208, and it is not public. [14]

How to read it. Documented: his tenure, his ethics agreement, the Pfizer approval and safety action during his tenure, the board seat, the committee chair and the pay. Apparent conflict: a former commissioner helping govern, and now chairing the regulatory-compliance committee of, a company whose products his agency regulates. Competing explanation: Pfizer's proxy cites his expertise in health care, public policy and the biopharmaceutical industry, and his FDA record includes real pressure on brand-name pricing tactics. [21][16] Unproven: that any FDA decision under him was shaped by the prospect of a Pfizer seat.

3. Tom Vilsack: the referee who went to work for the checkoff, then came back to referee (USDA → Dairy Management Inc./USDEC → USDA)

The office. Tom Vilsack, a former Iowa governor, was agriculture secretary for both of President Obama's terms. [32]

What the office oversees. Dairy farmers are required by federal law to pay into the dairy checkoff, a promotion and research program created under the Dairy Production Stabilization Act of 1983 and administered by USDA's Agricultural Marketing Service. Farmers pay 15 cents per hundredweight of milk, and the Secretary selects the national dairy board's members from nominations. [25] The Milwaukee Journal Sentinel reported that as secretary, "Vilsack's duties included overseeing the checkoff programs." [29] His USDA also made market decisions that reached dairy directly. In August 2016 it announced a $20 million purchase of about 11 million pounds of surplus cheese for food banks, under routine Section 32 surplus-purchase authority, after requests from Congress, the National Farmers Union, the American Farm Bureau and the National Milk Producers Federation. [26] That purchase fed people and steadied a glutted market. We found nothing linking it to his later job, and we do not suggest a link.

The job. On January 17, 2017, days before the Obama administration ended, the U.S. Dairy Export Council announced that Vilsack would become its president and CEO on February 1. [27] USDEC was founded in 1995 by Dairy Management Inc., the checkoff-funded organization behind national dairy promotion. USDEC calls itself a "non-profit, independent" membership organization, and its website says it is "Managed by Dairy Management Inc." [27] The pay ran through Dairy Management: its IRS Form 990 filings list Vilsack as an executive vice president, with total compensation of $800,557 for 2017 and $999,421 for 2018, his first full year. [28] The Journal Sentinel reported that his 2018 salary and bonus alone came to $930,090, more than four times his $200,000 Cabinet salary, and that Dairy Management received $159.7 million from the checkoff that year. [29] His January 2021 federal nominee disclosure reported $833,000 in USDEC salary for its reporting period, which covered 2020 and the first days of 2021, plus a housing allowance. [30]

The return. Then the door turned the other way. The Senate confirmed him as agriculture secretary again on February 23, 2021, by a vote of 92 to 7. [33] His ethics agreement committed him to resign from USDEC on confirmation and, for one year afterward, to stay out of specific-party matters in which USDEC was a party unless authorized. [31] In February 2021, USDA's designated ethics official wrote that he continued "to believe that Secretary Vilsack is in compliance with applicable laws and regulations governing conflicts of interest." [31] He also agreed to sign President Biden's ethics pledge. [31][35]

So the official who oversaw the checkoff left to lead a checkoff-founded group on checkoff-funded pay, then came back to oversee the checkoff. Every step was disclosed. The ethics agreement walled him off from USDEC's own matters for a year. It did not wall him off from the checkoff system as a whole, and no rule required it to.

The defense. A Dairy Management spokeswoman told the Journal Sentinel that its "salaries are within competitive levels of compensation for comparable positions," and the paper reported that its requests to interview Vilsack were denied. [29] Vilsack's own statement on taking the job described a career spent "as a tireless advocate for farmers." [27] Export promotion is a legitimate mission, and it is the one USDEC was created to pursue. [27]

Was wrongdoing found? None that we located. Lobbying disclosures list him only on filings from 2006 to 2008, before his first USDA term, and on none during his USDEC years. [36]

How to read it. Documented: USDA's oversight role, the job, the pay on Dairy Management's tax filings, the return, the ethics agreement and the compliance certification. Apparent conflict: farmer-paid checkoff money funded a near-$1 million package for a former overseer of the program, who then returned to oversee it. Unproven: that any decision in either term was made with that pay in mind.

Dairy farmers pay that checkoff even in years they operate at a loss. [29] Hold that next to the salary line, and then ask who the system was built to comfort.

4. Rick Perry: board, Cabinet, board (DOE → Energy Transfer)

The office. Rick Perry, the former Texas governor, was U.S. Secretary of Energy from March 2017 until December 2019. Before that he sat on the board of Energy Transfer Partners from February 2015 until December 2016. [42] He resigned from that board and the board of Sunoco Logistics effective December 31, 2016. [39] His ethics agreement committed him to sell his units in both partnerships within 90 days of confirmation and to stay out of matters affecting them while he held them. It also barred him from specific-party matters involving them unless he was authorized or received a waiver. [37] The Texas Tribune reported $171,000 in combined 2016 director fees from the two companies. [38] Trump's 2017 pledge, which every appointee was required to sign, added a two-year bar on specific-party matters involving former employers. [15]

What his department did. On June 29, 2017, Perry's Department of Energy approved an additional 0.33 billion cubic feet per day of liquefied natural gas exports from the proposed Lake Charles LNG project in Louisiana, which the department described as "jointly owned by the Texas-based Energy Transfer and the Anglo-Dutch based Royal Dutch Shell." [40] DOE found the added exports "not inconsistent with the public interest." It noted that it had already authorized the project to export up to 2 Bcf/d and had approved 21.33 Bcf/d of such exports nationwide. [40] In other words, this was an increment to an earlier approval, inside a nationwide export push. We found no document showing that Perry personally took part in the order, and his ethics commitments barred him from doing so without authorization. [37][15] What the record shows is narrower: his department approved an export increase for a project co-owned by a company whose board he had just left and would later rejoin.

The sharper questions came from Ukraine. A 2020 investigation by TIME, WNYC and ProPublica, published by The Texas Tribune, reported that Perry and his staff "worked to advance energy deals that were potentially worth billions of dollars to Perry's friends and political donors," and that two of the deals "seemed set to benefit Energy Transfer." Executives estimated the biggest at $20 billion. [44] Two ethics experts told the reporters his efforts violated federal regulations. The same report said Perry "appears to have stayed on the right side of the law." It reported that federal prosecutors in Manhattan had questioned at least four people about the deals and, according to two sources, that Perry was not a target. [44] Perry's spokesman said he "never connected or facilitated discussions" between Energy Transfer and Ukraine's state energy company in one of the deals and declined to comment on the others. Energy Transfer said it was "not aware of any contact between Secretary Perry and Ukrainian officials on Energy Transfer's behalf." [44]

The job. On January 1, 2020, weeks after leaving DOE, Perry was appointed a director of LE GP, LLC, the general partner of Energy Transfer LP. The company's filing said there were no arrangements or understandings behind the appointment. [41] Energy Transfer reported $174,997 in 2020 director pay: $75,000 in cash and $99,997 in unit awards. [42] He was still a director as of Energy Transfer's annual report filed in February 2026, which lists his 2025 director pay at $225,000 ($100,000 cash and $125,000 in unit awards) and his holdings at 166,742 common units. [43]

Was wrongdoing found? No charge or official finding that we located. The experts' view is an opinion reported by journalists, not an adjudication. [44] Lobbying disclosures we searched do not list him as a registered lobbyist.

How to read it. Documented: board seat before, a DOE export approval for an Energy Transfer project during, board seat after, the pay and the units. Allegation: experts' view, reported by journalists, that his Ukraine advocacy broke federal ethics regulations. Apparent conflict: a department promoting LNG exports while a former and future board employer was an LNG developer. Unproven: personal participation in any Energy Transfer decision at DOE. He denies facilitating the Ukraine discussions in question.

Round and round, like a car on a banked oval: board, Cabinet, board. The cooling-off rules governed the phone calls. They never governed the lap.

5. Meredith Attwell Baker: the vote in January, the job in May (FCC → Comcast/NBCUniversal → CTIA)

The office. Meredith Attwell Baker came to the Federal Communications Commission by way of both industry and government. From 1998 to 2000 she was director of congressional affairs for the wireless trade group CTIA. Under President George W. Bush she worked at the Commerce Department's National Telecommunications and Information Administration, finishing as its acting administrator. [49][52] President Obama nominated her to the FCC in 2009. At her confirmation hearing she wrote that she would "defer to General Counsel's decision as to any conflict of interest and would recuse myself as appropriate." [49] The Senate confirmed her by unanimous consent on July 24, 2009. [50] She joined the five-member commission that July as one of its two Republicans, for a term that ran to the end of June 2011. [51][53]

What she did in office. On January 18, 2011, the FCC approved Comcast's takeover of NBC Universal. The deal combined "the nation's largest cable operator and Internet service provider" with a company that "owns and develops some of the most valuable television and film content." The approval carried conditions that "generally will remain in effect for seven years." [54] The order records the vote. Chairman Genachowski and Commissioner Clyburn approved, Commissioners McDowell and Baker concurred, and Commissioner Copps dissented. [55] The Associated Press reported the vote as 4 to 1. [53] Baker's joint statement with McDowell said the deal "has the potential to bring exciting benefits to consumers that outweigh potential harms," called the commission's merger reviews "excessively coercive and lengthy," and concluded that "the Order goes too far." It closed: "To secure approval of the underlying transaction, we therefore concur." [55] Comcast closed the transaction ten days later, on January 28, 2011. [56]

The job. On May 11, 2011, less than four months after the vote, Comcast announced that Baker would join it as senior vice president of government affairs for NBCUniversal. [51] NBCUniversal's general counsel, Rick Cotton, said in the announcement: "I've seen Meredith's mastery of issues up close as we've worked together on issues at the FCC and NTIA." [51] The AP reported that she would leave the FCC on June 3, less than a month before her term was due to expire. [53] Comcast's federal lobbying reports list her as a lobbyist on all 11 quarterly reports from the third quarter of 2011 through the first quarter of 2014. Her listed former covered positions begin with "Commissioner, FCC." [57][58][59] In April 2014, CTIA named her its president and CEO, effective June 2, after "more than two years" at Comcast-NBCUniversal. [52] CTIA's tax return for the fiscal year ending December 2024 reports $6,132,509 in compensation for her as president and CEO, plus $108,017 in other compensation. [60] We did not find her Comcast pay in the sources we reviewed.

The rules she worked under. The FCC's general counsel later laid out the rules in writing for Congress. Under the criminal conflict-of-interest statute, 18 U.S.C. § 208, an employee negotiating for a job must stay out of matters that would have a "direct and predictable financial impact" on the prospective employer. [70][63] After leaving, she could not contact or appear before FCC employees on anyone else's behalf for two years, under § 207(c) as extended by the Obama ethics pledge. She also could not lobby covered executive-branch officials or noncareer senior executives for the rest of the Obama administration. [70][34] Separately, § 207(a) barred her from representing anyone before the government on specific-party matters she had worked on personally and substantially, for the life of each matter, and on matters pending under her responsibility in her final year, for two years. [70] None of those rules covered lobbying Congress, which she was free to do at once. [61] The disclosures fit that picture. On each of the 11 Comcast reports that list her, the issue areas she worked show only the House and Senate as the entities contacted. Those reports list contacts by issue area, not by individual lobbyist. [59]

Her side of it, and Comcast's. In a statement the FCC released on May 13, 2011, Baker said that "until late this spring" she had planned to seek a second term, and that this "was true all through the winter during consideration of the Comcast/NBCUniversal transaction and in the months after it was completed." She added: "Not once in my entire tenure as a Commissioner had anyone at Comcast or NBCUniversal approached me about potential employment." She said she sought the general counsel's advice when the opportunity arose in mid-April and recused herself on April 18 from any matters involving Comcast or NBCUniversal. "I have not only complied with the legal and ethical laws, but I also have gone further," she said, noting that she had not voted on any item at all since entering job discussions. [71] The FCC general counsel's account matches hers on the dates. She first contacted his office on April 13, 2011, "to discuss the procedures that she should follow" if she explored a job with NBCUniversal. On April 18 she told him in writing that she would recuse herself from matters affecting NBCUniversal or Comcast "on account of her intent to begin exploratory conversations." [70] Comcast said it did not begin discussions with her about a job until after the transaction had closed. [53] A fair reading of her concurrence also has to note that McDowell, the commission's other Republican, signed the same words, and that their objection was to the reach of the merger conditions rather than to the deal itself. [55]

The criticism. Craig Aaron of the advocacy group Free Press called the move "business as usual in Washington — where the complete capture of government by industry barely raises any eyebrows." [53] Free Press and CREDO Action said they had collected more than 130,000 letters seeking a congressional investigation. [62] On May 18, 2011, Rep. Darrell Issa, the California Republican who chaired the House Oversight Committee, wrote to the FCC chairman that her announcement "has generated questions surrounding the transition, especially in light of the recent FCC decisions related to her future employer." He asked five questions: what rules applied, what steps were taken, and when she notified the general counsel and began recusing. He wrote that "it is imperative that the public can trust the integrity of the process." [69]

Was wrongdoing found? None that we located. Issa's own letter said: "Based on the public statements of both Commissioner Baker and the FCC, it does not appear that she violated any of her legal or ethical obligations in accepting a position with Comcast." [69] Chairman Genachowski answered on May 26, 2011, enclosing the general counsel's responses described above. [70] We did not locate her FCC ethics agreement or her financial disclosure reports. Under federal rules, public financial disclosure reports are generally destroyed six years after they are filed. [72]

How to read it. Documented: the concurring vote and joint statement, the closing date, the announcement less than four months later, the April 13 and April 18 dates in the FCC's written answers to Congress, the Comcast lobbying registrations, the CTIA post and pay. Apparent conflict: a commissioner who argued for lighter merger conditions went to work for the merged company within months. Allegation: advocacy groups' claim that the move showed industry capture of the agency. Competing explanation: her concurrence matched her Republican colleague's, and she and Comcast both say no job contact came before mid-April. Unproven: any job contact before the vote. We found no document showing one.

Vote in January. Deal closed in January. Recusal in April. Job announced in May. As far as this record shows, every step was disclosed and every rule followed. The public is still asked to take the order of events on trust.

The scorecard

Figure	Public office	Policy or decision on the record	Industry role	Reported pay	Finding of wrongdoing
Billy Tauzin	House Energy & Commerce chair	Original cosponsor, conferee and yea vote on 2003 Medicare drug law with noninterference clause [1][2][3]	PhRMA president, 2005–2010 [5][6]	$4.6M total, 2009 [6]	None located [4][7]
Scott Gottlieb	FDA commissioner, 2017–2019 [13]	Biosimilars push; agency approval and safety action on Pfizer products during tenure [16][17][18]	Pfizer director since June 2019 [20][22]	$393,500, 2025 [21]	None located
Tom Vilsack	Agriculture secretary, 2009–2017 and again from 2021 [32][33]	Department oversaw dairy checkoff [25][29]	USDEC president/CEO and Dairy Management EVP, 2017–2021 [27][28]	$999,421, 2018 [28]	None located; USDA ethics official found compliance, 2021 [31]
Rick Perry	Energy secretary, 2017–2019 [42]	DOE approved added Lake Charles LNG exports; Ukraine deal advocacy reported [40][44]	Energy Transfer GP director since Jan. 2020 [41][43]	$225,000, 2025 [43]	No charge; experts alleged rule violations [44]
Meredith Attwell Baker	FCC commissioner, 2009–2011 [50][53]	Concurred in 2011 Comcast–NBCU approval; called conditions excessive [55]	Comcast/NBCUniversal lobbyist, 2011–2014; CTIA CEO from 2014 [51][59][52]	CTIA: $6.13M, FY2024 [60]; Comcast: not found	None located; Issa letter saw no apparent violation [69]

What the record tells us, and what it doesn't

Look at the cases side by side and one plain thing comes through. Nobody had to break a rule. The system let each of them move between writing or enforcing the rules and earning from the industries under those rules, with waiting periods on certain phone calls and recusal letters for certain files. Every move was disclosed somewhere. Hardly any of it is visible to the farmer, the patient or the ratepayer unless someone goes and gets it.

For contrast: what a proven case looks like. Darleen Druyun's case shows what the record looks like when a revolving-door case does end in a conviction. Until she retired in November 2002, Druyun was the Air Force's top career procurement officer, its principal deputy assistant secretary for acquisition and management. She joined Boeing in January 2003. [64][65] She was a career civil servant, not an elected or Senate-confirmed official, which is why she is not one of our five. In 2004 she pleaded guilty to conspiracy to violate the federal conflict-of-interest law, 18 U.S.C. § 208(a), for negotiating a job with Boeing while handling Boeing business. [64][66] According to court records, while negotiating a lease of 100 Boeing KC-767A tankers she agreed to a higher price than she believed appropriate. She did so "in her view, as a 'parting gift to Boeing'" and to ingratiate herself with her future employer, and she gave Boeing what she considered a rival manufacturer's proprietary pricing data. [64] In a supplemental statement filed with her October 2004 plea, she acknowledged that Boeing's hiring of her daughter and future son-in-law, along with her own wish to work there, "influenced her government decisions in matters affecting Boeing." Those decisions included a C-17 payment of about $412 million and a C-130 avionics award worth more than $4 billion, where she said "an objective selection authority may not have selected Boeing." [66] On October 1, 2004, a federal judge sentenced her to nine months in prison. [64] Government Executive reported seven more months in a halfway house or home detention, a $5,000 fine and 150 hours of community service. [67] In February 2005, the Government Accountability Office sustained rival bidders' protests of the C-130 award, ruling that the Air Force had failed to show that her "acknowledged bias" did not prejudice them. [66] Michael Sears, the Boeing chief financial officer who recruited her, was sentenced that month to four months in prison and a $250,000 fine. [68][65] In 2006 Boeing agreed to pay a record $615 million to resolve criminal and civil claims over her hiring and, separately, over its handling of competitors' information on launch contracts. [65]

That is what proof looks like: a plea, admissions in court filings, a sentence and an independent finding. The five cases above have none of that. There is no charge, no admission and no finding against any of the five, and we do not suggest they did anything like what Druyun admitted. The contrast is the point. Most of the revolving door turns inside what the law allows, and there the only check is the public's attention.

The fair counterargument deserves a full hearing. People who understand drug approval, commodity markets, pipelines or spectrum are rare. Government wants them, and industries want them afterward. Some of the best regulators come from industry and go back to it. Tighter rules, such as longer cooling-off periods, bans on board seats at companies an official directly regulated, or public disclosure of executive-branch job talks, would cost something. They would make experienced people harder to recruit. Voters and lawmakers should weigh that cost honestly.

But the burden of the doubt does not fall evenly. When a former overseer is paid with farmers' checkoff dollars, the farmers carry it. When a drug benefit is written to keep the government away from the bargaining table, patients and taxpayers carry it. When an energy secretary's former and future board employer stands to profit from export policy, ratepayers and the communities living beside the pipes and terminals carry it, whether or not anyone ever did anything wrong. When a commissioner who argued for lighter merger conditions goes to work for the merged company, the customers who live with those conditions carry the doubt. Concentrated power does not need a crime to tilt the field. It only needs the public to stop looking.

Marcus Aurelius, writing privately to himself while he ruled Rome, put the warning to the powerful plainly: "Take care that thou art not made into a Caesar, that thou art not dyed with this dye; for such things happen. Keep thyself then simple, good, pure, serious, free from affectation, a friend of justice." (Meditations, Book VI, section 30, translated by George Long) [45] He was not writing about lobbying law. He was writing about how office changes a person, and why it takes daily discipline to resist it.

So here is what stays within our reach. Read the vote. Read the order. Read the proxy and the ethics agreement. Put them in order and ask the question out loud. Officials answer to the public, and the public can only hold anyone to account for what it actually knows.

The door will keep turning. Our job is to keep the lights on in the hallway.

---

A note on corrections and responses: Anyone named in this article who believes something here is inaccurate, incomplete or unfair is invited to respond or request a correction through our contact form at https://www.loracing.com/#block-f604ec3f495cde650e97. We will review every submission against the public record and update the article where the record supports a change. We did not contact the people named before publication; their responses quoted here come from the published record.

Methods and limits: Cases were chosen from elected members of Congress and presidentially appointed, Senate-confirmed officials, for prominence, the size of the policy action, a clear documented sequence, documented industry benefit, spread across five different offices (with two cases involving the drug industry) and the availability of each person's own account. A career official's criminal case, Druyun's, appears only as a contrast. This is an illustrative sample, not a representative or complete count. Every factual claim is tied to a numbered source below, reopened on November 9, 2026. Offices are described as of the dates given; Gottlieb's and Perry's current board seats are as of their companies' 2026 filings. We do not characterize motives. Where a claim rests on journalism or an advocacy group, we say so. Lobbying records come from the federal Lobbying Disclosure Act database as queried on November 9, 2026. We could not obtain the original Milwaukee Journal Sentinel pages, which are behind a paywall, and cite a republication instead, cross-checked against Dairy Management's IRS data. Perry's ethics agreement is cited from a copy of the filed document hosted by The Texas Tribune. Baker's recusal dates come from the FCC general counsel's written answers to Rep. Issa. We did not locate her FCC ethics agreement or financial disclosure reports, and her Comcast pay does not appear in the SEC filings we searched.

Sources

1. Office of the Clerk, U.S. House: Roll Call 669, H.R. 1 conference report, Nov. 22, 2003. https://clerk.house.gov/Votes/2003669
2. Library of Congress/GPO bill status record, H.R. 1 (108th Congress): sponsor, original cosponsors, conferees, Public Law 108-173. https://www.govinfo.gov/bulkdata/BILLSTATUS/108/hr/BILLSTATUS-108hr1.xml
3. 42 U.S.C. 1395w-111(i), noninterference clause, with 2022 amendment notes (Legal Information Institute). https://www.law.cornell.edu/uscode/text/42/1395w-111
4. NBC News (Mike Stuckey, Mar. 22, 2006): Tauzin aided drug firms, then they hired him. https://www.nbcnews.com/id/wbna11714763
5. Los Angeles Times (Ricardo Alonso-Zaldivar, Dec. 16, 2004): Congressman's new job is top drug lobbyist. https://www.latimes.com/archives/la-xpm-2004-dec-16-na-tauzin16-story.html
6. NPR Shots (Dec. 1, 2010): Drug lobby's tax filings reveal big spending in health debate. https://www.npr.org/sections/health-shots/2010/12/01/131731212/drug-lobby-s-tax-filings-reveal-big-spending-in-health-debate-role
7. Public Citizen (advocacy group), Jan. 28, 2004: Public Citizen calls for ethics investigation of Tauzin. https://www.citizen.org/news/public-citizen-calls-for-ethics-investigation-of-tauzin/
8. ProPublica (Olga Pierce, Oct. 20, 2009): Medicare drug planners now lobbyists, with billions at stake. https://www.propublica.org/article/medicare-drug-planners-now-lobbyists-with-billions-at-stake-1020
9. Congress.gov: S. 1 (110th), Honest Leadership and Open Government Act of 2007, CRS summary (P.L. 110-81). https://www.congress.gov/bill/110th-congress/senate-bill/1
10. 18 U.S.C. 207, restrictions on former officers and employees (Legal Information Institute). https://www.law.cornell.edu/uscode/text/18/207
11. Lobbying Disclosure Act database (lda.gov API): PhRMA filings listing Billy Tauzin as a lobbyist, queried Nov. 9, 2026. https://lda.gov/api/v1/filings/?registrant_id=31350&lobbyist_name=Tauzin
12. Lobbying Disclosure Act database (lda.gov API): all filings naming a lobbyist Tauzin, queried Nov. 9, 2026. https://lda.gov/api/v1/filings/?lobbyist_name=Tauzin
13. U.S. Food and Drug Administration: Scott Gottlieb, M.D., leadership page. https://www.fda.gov/about-fda/fda-leadership-1907-today/scott-gottlieb
14. U.S. Office of Government Ethics: Scott Gottlieb ethics agreement, Mar. 28, 2017. https://extapps2.oge.gov/201/Presiden.nsf/PAS+Index/BD4592091CA01C31852580F2002C008C/$FILE/Gottlieb%2C%20Scott%20finalEA.pdf
15. Executive Order 13770, Ethics Commitments by Executive Branch Appointees, Jan. 28, 2017 (82 Fed. Reg., Feb. 3, 2017). https://www.govinfo.gov/content/pkg/FR-2017-02-03/pdf/2017-02450.pdf
16. FDA via PR Newswire (July 18, 2018): Gottlieb remarks on the Biosimilars Action Plan. https://www.prnewswire.com/news-releases/remarks-from-fda-commissioner-scott-gottlieb-md-as-prepared-for-delivery-at-the-brookings-institution-on-the-release-of-the-fdas-biosimilars-action-plan-300683127.html
17. Pfizer press release (May 15, 2018): Retacrit approved by U.S. FDA. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_biosimilar_retacrit_epoetin_alfa_epbx_approved_by_u_s_fda
18. FDA via PR Newswire (Feb. 25, 2019): FDA responds to safety signal in required postmarketing trial for Xeljanz. https://www.prnewswire.com/news-releases/fda-responds-to-safety-signal-reported-in-required-postmarketing-trial-for-xeljanz-300801561.html
19. Public Citizen Health Letter (advocacy group; Michael Carome, Oct. 2019): Revolving door to FDA Commissioner's office. https://www.citizen.org/article/outrage-of-the-month-revolving-door-to-fda-commissioners-office-sows-distrust-in-agency/
20. Pfizer Inc. Form 8-K (June 27, 2019): election of Scott Gottlieb as director. https://www.sec.gov/Archives/edgar/data/78003/000007800319000049/form8-k_6272019docx.htm
21. Pfizer Inc. 2026 proxy statement (DEF 14A, filed Mar. 12, 2026): director biography, independence review and 2025 director compensation. https://www.sec.gov/Archives/edgar/data/78003/000007800326000033/pfe-20260312.htm
22. Pfizer Inc. Form 8-K (Apr. 23, 2026): annual meeting vote results. https://www.sec.gov/Archives/edgar/data/78003/000007800326000044/pfe-20260423.htm
23. CNBC (Angelica Peebles, July 2, 2019): Sen. Warren calls on ex-FDA chief Gottlieb to resign from Pfizer board. https://www.cnbc.com/2019/07/02/sen-warren-calls-on-ex-fda-chief-gottlieb-to-resign-from-pfizer-board.html
24. Executive Order 13983, Revocation of Executive Order 13770, Jan. 19, 2021 (86 Fed. Reg. 6835). https://www.govinfo.gov/content/pkg/FR-2021-01-25/pdf/2021-01713.pdf
25. USDA Agricultural Marketing Service: National Dairy Promotion and Research Board (dairy checkoff). https://www.ams.usda.gov/rules-regulations/research-promotion/dairy
26. USDA press release (Aug. 23, 2016): USDA to purchase surplus cheese for food banks and families in need. https://www.usda.gov/media/press-releases/2016/08/23/usda-purchase-surplus-cheese-food-banks-and-families-need-continue
27. U.S. Dairy Export Council news release (Jan. 17, 2017): Tom Vilsack to take helm of USDEC. https://www.usdec.org/newsroom/news-releases/news-releases-archives/news-release-01/17/2017
28. ProPublica Nonprofit Explorer: Dairy Management Inc. (EIN 36-3992031), IRS Form 990 compensation data, tax years 2016-2020. https://projects.propublica.org/nonprofits/organizations/363992031
29. eDairy News republication (Dec. 3, 2019) of a Milwaukee Journal Sentinel story by Cary Spivak: Vilsack is the top paid executive at Dairy Management. https://en.edairynews.com/ex-agriculture-secretary-tom-vilsack-is-the-top-paid-executive-at-dairy-management/
30. U.S. Office of Government Ethics: Thomas J. Vilsack nominee financial disclosure (OGE Form 278e, signed Jan. 4, 2021) with Feb. 2021 amendment. https://extapps2.oge.gov/201/Presiden.nsf/PAS+Index/67E814B59083C0428525865900317D9D/$FILE/Vilsack%2C%20Thomas%20J.%20%20AMENDEDfinal278.pdf
31. U.S. Office of Government Ethics: Thomas J. Vilsack ethics agreement (Jan. 8, 2021) with Feb. 25, 2021 supplement. https://extapps2.oge.gov/201/Presiden.nsf/PAS+Index/86A494E568E6AC938525865900317E65/%24FILE/Vilsack,%20Thomas%20J.%20%20AMENDEDfinalEA.pdf
32. Roll Call (Jan. 11, 2021): Biden's choice to lead USDA helped monitor OxyContin maker. https://rollcall.com/2021/01/11/bidens-choice-to-lead-usda-helped-monitor-oxycontin-maker/
33. U.S. Senate Daily Press floor log, Feb. 23, 2021: Vilsack confirmed 92-7. https://www.dailypress.senate.gov/tuesday-february-23-2021/
34. Executive Order 13490, Ethics Commitments by Executive Branch Personnel, Jan. 21, 2009 (74 Fed. Reg., Jan. 26, 2009). https://www.govinfo.gov/content/pkg/FR-2009-01-26/pdf/E9-1719.pdf
35. Executive Order 13989, Ethics Commitments by Executive Branch Personnel, Jan. 20, 2021 (86 Fed. Reg. 7029). https://www.govinfo.gov/content/pkg/FR-2021-01-25/pdf/2021-01762.pdf
36. Lobbying Disclosure Act database (lda.gov API): filings naming a lobbyist Vilsack, queried Nov. 9, 2026. https://lda.gov/api/v1/filings/?lobbyist_name=Vilsack
37. James Richard Perry ethics agreement to DOE ethics official, Jan. 9, 2017 (copy of the OGE-filed document hosted by The Texas Tribune). https://static.texastribune.org/media/documents/Perry_James_Richard__finalEA.pdf
38. The Texas Tribune (Jay Root, Jan. 11, 2017): Energy secretary pick Rick Perry to divest of holdings that could present conflicts. https://www.texastribune.org/2017/01/11/perry-divest-holdings-could-present-conflict/
39. Sunoco Logistics Partners L.P. Form 8-K (report date Jan. 5, 2017): Perry resignation from the Sunoco and Energy Transfer Partners boards effective Dec. 31, 2016. https://www.sec.gov/Archives/edgar/data/1161154/000116115417000002/a8-kperryresignation.htm
40. U.S. Department of Energy (June 29, 2017): DOE authorizes additional LNG exports from Lake Charles. https://www.energy.gov/articles/us-department-energy-authorizes-additional-liquefied-natural-gas-exports-lake-charles
41. Energy Transfer LP Form 8-K (event Jan. 1, 2020): Perry appointed director of LE GP, LLC. https://www.sec.gov/Archives/edgar/data/1276187/000127618720000004/et8-k01032020newdirect.htm
42. Energy Transfer LP Form 10-K for fiscal 2020: director biographies and 2020 director compensation. https://www.sec.gov/Archives/edgar/data/1276187/000127618721000034/et-20201231.htm
43. Energy Transfer LP Form 10-K for fiscal 2025 (filed Feb. 19, 2026): directors, 2025 director compensation and unit ownership. https://www.sec.gov/Archives/edgar/data/1276187/000127618726000013/et-20251231.htm
44. TIME, WNYC and ProPublica investigation, published by The Texas Tribune (Sept. 10, 2020): As energy secretary, Rick Perry mixed money and politics in Ukraine. https://www.texastribune.org/2020/09/10/rick-perry-energy-secretary-ukraine/
45. Marcus Aurelius, Meditations (Thoughts of the Emperor Marcus Aurelius Antoninus), trans. George Long, Project Gutenberg eBook 15877. https://www.gutenberg.org/cache/epub/15877/pg15877.txt
46. Lobbying Disclosure Act report (LD-2), Pharmaceutical Research and Manufacturers of America, 2006 year-end (image filing; lda.gov API lists "TAUZIN, BILLY," covered position "MEMBER OF CONGRESS"). https://lda.gov/filings/public/filing/f0e5cb2f-9fb3-4c9d-8fe5-995cc0a9b242/print/
47. Lobbying Disclosure Act report (LD-2), Pharmaceutical Research and Manufacturers of America, 2nd quarter 2010 (lists Billy Tauzin). https://lda.gov/filings/public/filing/630f8816-034c-4852-9aa1-dc9324c599be/print/
48. Lobbying Disclosure Act report (LD-2), Tauzin Strategic Networks for Endo Pharmaceuticals, 4th quarter 2012. https://lda.gov/filings/public/filing/ecc4494a-958d-472d-add3-c1c51e6d5ecb/print/
49. U.S. Senate Commerce Committee, S. Hrg. 111-357: Nominations of Mignon L. Clyburn and Meredith Attwell Baker to the FCC, July 15, 2009 (questionnaire responses). https://www.govinfo.gov/content/pkg/CHRG-111shrg52755/html/CHRG-111shrg52755.htm
50. U.S. Senate Commerce Committee: Nominees confirmed by unanimous consent, July 24, 2009. https://www.commerce.senate.gov/dem-issues/nominations/page/13/
51. Comcast Corporation news release (May 11, 2011): Meredith Attwell Baker, FCC Commissioner, to join Comcast as Senior Vice President of Government Affairs, NBCUniversal. https://corporate.comcast.com/news-information/news-feed/meredith-attwell-baker-fcc-commissioner-to-join-comcast-as-senior-vice-president-of-government-affairs-nbcuniversal
52. CTIA via PR Newswire (Apr. 23, 2014): Meredith Attwell Baker named Chief Executive Officer of CTIA-The Wireless Association. https://www.prnewswire.com/news-releases/meredith-attwell-baker-named-chief-executive-officer-of-ctia-the-wireless-association-256356601.html
53. Associated Press via NBC News (Joelle Tessler, May 11, 2011): Regulator joins Comcast after she OK'd NBC deal. https://www.nbcnews.com/id/wbna42998680
54. Federal Communications Commission news release (Jan. 18, 2011): FCC grants approval of Comcast-NBCU transaction. https://docs.fcc.gov/public/attachments/DOC-304134A1.pdf
55. Federal Communications Commission, Memorandum Opinion and Order, MB Docket No. 10-56, FCC 11-4 (adopted Jan. 18, 2011; released Jan. 20, 2011), including the joint concurring statement of Commissioners McDowell and Baker. https://docs.fcc.gov/public/attachments/FCC-11-4A1.pdf
56. Comcast Corporation Form 8-K (report date Jan. 28, 2011): completion of the NBCUniversal transaction. https://www.sec.gov/Archives/edgar/data/1166691/000095010311000353/dp20918_8k.htm
57. Lobbying Disclosure Act report (LD-2), Comcast Corporation, 3rd quarter 2011 (lists Meredith Baker; covered positions include "Commissioner, FCC"). https://lda.gov/filings/public/filing/381e25cc-88d3-48df-9a8a-84fb9cd25d57/print/
58. Lobbying Disclosure Act report (LD-2), Comcast Corporation, 1st quarter 2014 (lists Meredith Baker). https://lda.gov/filings/public/filing/57dd3d25-50df-44b9-92eb-058f4072ea25/print/
59. Lobbying Disclosure Act database (lda.gov API): Comcast filings listing Meredith Baker, 3Q 2011 through 1Q 2014 (11 reports), queried Nov. 9, 2026. https://lda.gov/api/v1/filings/?lobbyist_name=Baker&registrant_name=Comcast
60. ProPublica Nonprofit Explorer: CTIA (EIN 52-1347628), IRS Form 990 data, fiscal year ending Dec. 2024. https://projects.propublica.org/nonprofits/organizations/521347628
61. The New York Times (Edward Wyatt, May 13, 2011): F.C.C. Commissioner defends taking Comcast job. https://archive.nytimes.com/mediadecoder.blogs.nytimes.com/2011/05/13/f-c-c-commissioner-defends-taking-comcast-job/
62. Free Press (advocacy group) press release (May 20, 2011): Issa responds to public outcry over Baker departure, questions FCC. https://www.freepress.net/news/issa-responds-public-outcry-over-baker-departure-questions-fcc
63. 5 C.F.R. 2635.604, recusal while seeking employment (current text; Legal Information Institute). https://www.law.cornell.edu/cfr/text/5/2635.604
64. U.S. Air Force, Air Force Print News (Oct. 4, 2004): Former Air Force official gets nine months in prison. https://www.af.mil/News/Article-Display/Article/135899/former-air-force-official-gets-nine-months-in-prison/
65. U.S. Department of Justice press release #06-412 (June 30, 2006): Boeing to pay United States record $615 million to resolve fraud allegations. https://www.justice.gov/archive/opa/pr/2006/June/06_civ_412.html
66. U.S. Government Accountability Office bid-protest decision B-295401 et al., Lockheed Martin Aeronautics Co.; L-3 Communications Integrated Systems; BAE Systems (Feb. 24, 2005), quoting Druyun's supplemental statement of facts. https://www.gao.gov/products/b-295401.3%2Cb-293401.2%2Cb-295401%2Cb-295401.4%2Cb-295401.5%2Cb-295401.6%2C
67. Government Executive (Oct. 2004): Ex-Pentagon procurement executive gets jail time. https://www.govexec.com/defense/2004/10/ex-pentagon-procurement-executive-gets-jail-time/17737/
68. Associated Press via NBC News (Feb. 18, 2005): Ex-Boeing exec gets 4 months in prison. https://www.nbcnews.com/id/wbna6993477
69. Letter from Rep. Darrell Issa, Chairman, House Committee on Oversight and Government Reform, to FCC Chairman Julius Genachowski (May 18, 2011), posted by the FCC. https://docs.fcc.gov/public/attachments/DOC-306973A2.pdf
70. Letter from FCC Chairman Julius Genachowski to Rep. Darrell Issa (May 26, 2011), with the FCC General Counsel's responses. https://docs.fcc.gov/public/attachments/DOC-306973A1.pdf
71. FCC news release (May 13, 2011): Statement of Commissioner Meredith Attwell Baker. https://docs.fcc.gov/public/attachments/DOC-306569A1.pdf
72. 5 C.F.R. 2634.603(g), retention of public financial disclosure reports (Legal Information Institute). https://www.law.cornell.edu/cfr/text/5/2634.603